Tetradecylthioacetic acid downregulates cyclooxygenase 2 in the renal cortex of two-kidney, one-clip hypertensive rats

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 295, Issue 6, 2008, Pages

  Bivol, Liliana Monica ^a   Hultström, Michael ^a   Gudbrandsen, Oddrun A ^a,b   Berge, Rolf K ^a,b   Iversen, Bjarne M ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Angiotensin II; Cyclooxygenase; Prostaglandin E2; Renal blood flow

Indexed keywords

ACETIC ACID DERIVATIVE; ANGIOTENSIN II; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROSTAGLANDIN E2; TETRADECYLTHIOACETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; KIDNEY BLOOD FLOW; KIDNEY CORTEX; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; REGULATORY MECHANISM; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CONSTRICTION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HYPERTENSION, RENOVASCULAR; INFUSIONS, SUBCUTANEOUS; INJECTIONS, INTRA-ARTERIAL; KIDNEY CORTEX; MALE; MEMBRANE PROTEINS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RATS; RATS, WISTAR; RENAL ARTERY; RENAL CIRCULATION; SULFIDES; TIME FACTORS;

EID: 57749099129     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00850.2007     Document Type: Article

References (56)

1. Amiri F, Garcia R. Renal angiotensin II receptor regulation in two-kidney, one clip hypertensive rats: effect of ACE inhibition. Hypertension 30: 337-344, 1997.
2. Asiedu D, Aarsland A, Skorve J, Svardal AM, Berge RK. Fatty acid metabolism in liver of rats treated with hypolipidemic sulphur-substituted fatty acid analogues. Biochim Biophys Acta 1044: 211-221, 1990.
3. Berge K, Tronstad KJ, Flindt EN, Rasmussen TH, Madsen L, Kristiansen K, Berge RK. Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis 22: 1747-1755, 2001.
4. Berge RK, Skorve J, Tronstad KJ, Berge K, Gudbrandsen OA, Grav H. Metabolic effects of thia fatty acids. Curr Opin Lipidol 13: 295-304, 2002.
5. Bivol LM, Berge RK, Iversen BM. Differential effect of tetradecythioacetic acid (TTA) on the renin-angiotensin system and blood pressure in SHR and 2-kidney, 1-clip hypertension. Am J Physiol Renal Physiol 293: F839-F845, 2007.
6. Bivol LM, Berge RK, Iversen BM. Tetradecylthioacetic acid prevents the inflammatory response in two-kidney, one-clip hypertension. Am J Physiol Regul Integr Comp Physiol 294: R438-R447, 2008.
7. Bivol LM, Vagnes OB, Iversen BM. The renal vascular response to ANG II injection is reduced in the nonclipped kidney of two-kidney, one-clip hypertension. Am J Physiol Renal Physiol 289: F393-F400, 2005.
8. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96: 354-360, 1995.
9. Cervenka L, Wang CT, Mitchell KD, Navar LG. Proximal tubular angiotensin II levels and renal functional responses to AT1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats. Hypertension 33: 102-107, 1999.
10. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926-13931, 2002.
11. Deng A, Wead LM, Blantz RC. Temporal adaptation of tubuloglomerular feedback: effects of COX-2. Kidney Int 66: 2348-2353, 2004.
12. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol Regul Integr Comp Physiol 265: R726-R732, 1993.
13. Dyroy E, Yndestad A, Ueland T, Halvorsen B, Damas JK, Aukrust P, Berge RK. Antiinflammatory effects of tetradecylthioacetic acid involve both peroxisome proliferator-activated receptor alpha-dependent and -independent pathways. Arteriosclerosis Throm Vasc Biol 25: 1364-1369, 2005.
14. Finn WF, Arendshorst WJ. Effect of prostaglandin synthetase inhibitors on renal blood flow in the rat. J Physiol 231: 1541-1545, 1976.
15. Gudbrandsen OA, Hultstrom M, Leh S, Monica Bivol L, Vagnes O, Berge RK, Iversen BM. Prevention of hypertension and organ damage in 2-kidney, 1-clip rats by tetradecylthioacetic acid. Hypertension 48: 460-466, 2006.
16. Guo DF, Sun YL, Hamet P, Inagami T. The angiotensin II type 1 receptor and receptor-associated proteins. Cell Res 11: 165-180, 2001.
17. Hahne B, Selen G, Erik A, Persson G. Indomethacin inhibits renal functional adaptation to nephron loss. Renal Physiol 7: 13-21, 1984.
18. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 281: F1-F11, 2001.
19. Harrison-Bernard LM, El-Dahr SS, O'Leary DF, Navar LG. Regulation of angiotensin II type 1 receptor mRNA and protein in angiotensin II-induced hypertension. Hypertension 33: 340-346, 1999.
20. Hartner A, Goppelt-Struebe M, Hilgers KF. Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension. Hypertension 31: 201-205, 1998.
21. Helle F, Vagnes OB, Iversen BM. Angiotensin II-induced calcium signaling in the afferent arteriole from rats with two-kidney, one-clip hypertension. Am J Physiol Renal Physiol 291: F140-F147, 2006.
22. Iversen BM, Heyeraas KJ, Sekse I, Andersen KJ, Ofstad J. Autoregulation of renal blood flow in two-kidney, one-clip hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 251: F245-F250, 1986.
23. Jaimes EA, Tian RX, Pearse D, Raij L. Up-regulation of glomerular COX-2 by angiotensin II: role of reactive oxygen species. Kidney Int 68: 2143-2153, 2005.
24. Kim SM, Chen L, Mizel D, Huang YG, Briggs JP, Schnermann J. Low plasma renin and reduced renin secretory responses to acute stimuli in conscious COX-2-deficient mice. Am J Physiol Renal Physiol 292: F415-F422, 2007.
25. Kobayashi T, Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostagland Lipid Mediat 68-69: 557-573, 2002.
26. Mann B, Hartner A, Jensen BL, Hilgers KF, Hocherl K, Kramer BK, Kurtz A. Acute upregulation of COX-2 by renal artery stenosis. Am J Physiol Renal Physiol 280: F119-F125, 2001.
27. Martinez-Maldonado M. Pathophysiology of renovascular hypertension. Hypertension 17: 707-719, 1991.
28. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272-277, 1999.
29. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, Kudo I. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275: 32783-32792, 2000.
30. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 39: 316-322, 2002.
31. Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD. Unraveling the Mystery of Goldblatt Hypertension. News Physiol Sci 13: 170-176, 1998.
32. Okumura T, Hayashi I, Ikezawa T, Yamanaka M, Takata T, Fujita Y, Saigenji K, Yamashina S, Majima M. Cyclooxygenase-2 inhibitors attenuate increased blood pressure in renovascular hypertensive models, but not in deoxycorticosterone-salt hypertension. Hypertens Res 25: 927-938, 2002.
33. Olivares-Reyes JA, Smith RD, Hunyady L, Shah BH, Catt KJ. Agonist-induced signaling, desensitization, and internalization of a phosphorylation-deficient AT1A angiotensin receptor. J Biol Chem 276: 37761-37768, 2001.
34. Opay AL, Mouton CR, Mullins JJ, Mitchell KD. Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 291: F612-F618, 2006.
35. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Creminon C, Maclouf J, Potrono C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmac Exp Ther 271: 1705-1712, 1994.
36. Persson AE, Hahne B, Selen G. The effect of tubular perfusion with PGE2, PGF2 alpha, and PGI2 on the tubuloglomerular feedback control in the rat. Can J Physiol Pharmacol 61: 1317-1323, 1983.
37. Persson AE, Ollerstam A, Liu R, Brown R. Mechanisms for macula densa cell release of renin. Acta Physiol Scand 181: 471-474, 2004.
38. Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, Chalfant CE, Obeid LM, Hannun YA. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J 17: 1411-1421, 2003.
39. Ploth DW. Angiotensin-dependent renal mechanisms in two-kidney, one-clip renal vascular hypertension. Am J Physiol Renal Fluid Electrolyte Physiol 245: F131-F141, 1983.
40. Richter CM, Godes M, Wagner C, Maser-Gluth C, Herzfeld S, Dorn M, Priem F, Slowinski T, Bauer C, Schneider W, Neumayer HH, Kurtz A, Hocher B. Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats. J Hypertens 22: 191-198, 2004.
41. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 9: 1087-1108, 2008.
42. Roig F, Llinas MT, Lopez R, Salazar FJ. Role of cyclooxygenase-2 in the prolonged regulation of renal function. Hypertension 40: 721-728, 2002.
43. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR-(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43: 661-666, 2004.
44. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59: 207-224, 2007.
45. Sawano H, Haneda M, Sugimoto T, Inoki K, Koya D, Kikkawa R. 15-Deoxy-delta12,14-prostaglandin J2 inhibits IL-1beta-induced cyclooxygenase-2 expression in mesangial cells. Kidney Int 61: 1957-1967, 2002.
46. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387-437, 2004.
47. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 107: 1491-1495, 2001.
48. Swinney DC, Mak AY, Barnett J, Ramesha CS. Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. J Biol Chem 272: 12393-12398, 1997.
49. Theilig F, Debiec H, Nafz B, Ronco P, Nusing R, Seyberth HW, Pavenstadt H, Bouby N, Bachmann S. Renal cortical regulation of COX-1 and functionally related products in early renovascular hypertension (rat). Am J Physiol Renal Physiol 291: F987-F994, 2006.
50. Todorov VT, Desch M, Schmitt-Nilson N, Todorova A, Kurtz A. Peroxisome proliferator-activated receptor-gamma is involved in the control of renin gene expression. Hypertension 50: 939-944, 2007.
51. Todorov VT, Desch M, Schubert T, Kurtz A. The Pal3 promoter sequence is critical for the regulation of human renin gene transcription by peroxisome proliferator-activated receptor-γ. Endocrinology 149: 4647-4657, 2008.
52. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 38: 97-120, 1998.
53. Vila E, Salaices M. Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol 288: H1016-H1021, 2005.
54. Waldner C, Heise G, Schror K, Heering P. COX-2 inhibition and prostaglandin receptors in experimental nephritis. Eur J Clin Invest 33: 969-975, 2003.
55. Wang JL, Cheng HF, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 34: 96-101, 1999.
56. Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther 283: 1069-1075, 1997.